{"name":"BicycleTx Limited","slug":"bicycletx-limited","ticker":"","exchange":"","domain":"bicycletxlimited.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BT5528","genericName":"BT5528","slug":"bt5528","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BT8009","genericName":"BT8009","slug":"bt8009","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BT5528","genericName":"BT5528","slug":"bt5528","phase":"phase_2","mechanism":"BT5528 is a small molecule inhibitor of the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"BT8009","genericName":"BT8009","slug":"bt8009","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOdElzWGhmNzlVQ3JGZ3hPSF8xc0xHcHlkWWVpSkpUcVo2SVh6aFZ6azNpb2xVUGZkVTRMbGE1aXMyZzlHY3hkeGN0dXR3eGItdXgxelJWUGxyT0RGRGU5c0ZaM09OdDVMbjQ3WHhvRW1kWDd2d3pBZ0VBeUxMX2N4ZllobUxselJQRjlKYlQ2UENlbXU3RWxZ?oc=5","date":"2025-08-08","type":"pipeline","source":"Fierce Biotech","summary":"Bicycle lays off 25% of workforce as Genentech rides away from R&D pact - Fierce Biotech","headline":"Bicycle lays off 25% of workforce as Genentech rides away from R&D pact","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}